Pharma 4.0, Thursday 1 March 2018


Organiser's Welcome Remarks

Alfred Scheidegger

Chair's Opening Remarks

Alfred Scheidegger, Chief Executive Officer, Nextech Invest

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng

Venture capital funding for the biotech industry

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important healthcare priorities, the role of the VC becomes even more crucial and necessary for early stage biotech company and its success. Find out how venture capitalists can tap on knowledge learnt from more established biotech ecosystem and apply these lessons in Asia. 
John Connolly

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
Panel discussion

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Speed Networking


Exhibition Visit & Networking Refreshments

Pharma 4.0: Clinical Research

Pharma 4.0

Chair's Opening Remarks

Shwen Gwee
Pharma 4.0

Digital trends impacting clinical trials

  • An overview on how data can transform pharma trials, from recruiting patients to real time drug performance evaluation
  • Using digital tools to optimise site selection, identification and engagement
  • Enhancing patient recruitment and compliance in trials conduction
Woong Yang Park
Pharma 4.0

Genome data mining and analysis for new drug discovery

  •     Identifying key gaps between current clinical trial methods with personalised treatment  
  •     Exploring key methods in genomics data mining and matching with patients to identify personalised treatment 
  •     Case study from Samsung Genomic Institute on the pathway towards personalised treatment

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 1: Innovative platforms for small molecules and gene therapy drug development

Table 2: Avoiding delays to the clinic

John Moore, Director of Global Clinical Business Development, Vetter Pharma International

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: Why don’t we have an ICI in breast cancer – yet?

Stefan Gluck, Vice President of Global Medical Affairs, Celgene

Table 6: Working on a start-up setting, from clinical development to commercialisation

Table 7: AI& Big data in drug discovery

Table 8: Preparation steps to brace healthcare & pharma digital transformation

round tables

Table 9: Reconciling the diversified pharma regulations in Asia


Exhibition Visit & Networking Lunch

Pharma 4.0: Patient Centricity

Pharma 4.0

Chair's Opening Remarks

Oscar Luo
Pharma 4.0

Big data & AI in digital rare disease patient recruitment

  • Using supercomputer and AI in matching patients to trials
  • Aligning your strategy & planning with R&D objectives
  • Evaluating and improvising planned digital clinical trial strategy
Cherie Lim
Pharma 4.0

Moving towards personalised medicine: Using big data to predict and customise treatment

  • Using digital to deliver better patient outcomes
  • Embracing digital reporting for stronger performance across key R&D capabilities
  • Addressing the potential compliance and cybersecurity risks in R&D digitalisation
Session led by: iqvia
Marimuthu Palaniswami
Pharma 4.0

The Internet of Medical Things (IoMT): Deep technology in patient monitoring, electronic disease surveillance, modelling and beyond

  • Generating and collecting electronic data and passive records from internet, mobile phones etc.
  • Designing participatory platforms and interactive digital infrastructure to allow better data collection
  • Combining e-health record (EHR), traditional and non-traditional digital data in disease surveillance, prediction and modelling
Marimuthu Palaniswami, Professor, Director, University of Melbourne

Exhibition Visit & Networking Refreshments

Pharma 4.0: Digital Operation

Pharma 4.0

Better decision making with big data analytics

  • Making sense of huge data volumes when using data analytics
  • Building real-time analysis capabilities for useful information collected from variable sources
  • Using big data in production lines to increase maintenance efficiency, improve availability and optimise maintenance costs
Pharma 4.0

Asset management and fleet tracking with IoT

  • Achieving greater visibility of products with multiple sensors on packages, trailers, warehouses and more
  • Enabling real time monitoring from pick up to delivery
  • Real-time track and trace to maximise product integrity
Kasper Jerlang
Pharma 4.0

Multichannel transformation and digital marketing strategies in Asia (Topic to be finalised)

    style="font-size: 10.0pt;">
  •     Building digital channels to better engage patients
  •     Using deep technology to optimise life cycle management
  •     Case study

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 19/Jan/18 08:15